, 6) Cancer drugs in general because these drugs were/are created to extend life, 7) Rheumatoid Arthritis Part B drugs (e.g. TNF Inhibitors such as Remicade) and 8) Multiple Myeloma Part B drugs – bortezomib, carfilzomib, …show more content…
In conclusion, we applaud CMS for issuing the proposed rule on Medicare Part B drug payment models. We believe it is important to test the next generation of value based purchasing models that will help balance pharmaceutical innovation with affordability while having the patient at the center of care delivery. We believe that: 1) Value Based Purchasing tools will lead to better value and higher quality for patients, 2) the Part B Payment model will increase patient access and 3) the model should consider use of utilization management for Part B drugs.
Thank you for the opportunity to comment on this proposal. If you have any questions regarding the comments or would like further information, please contact me at